泼尼松与安慰剂对反复种植失败患者体外受精后活产的影响:一项随机临床试验
该双盲、安慰剂对照随机临床试验在中国8家生殖中心纳入715例有2次及以上胚胎移植失败史、取卵时年龄小于38岁、计划行冻融胚胎移植且有好质量胚胎的妇女,比较每日口服10 mg泼尼松与安慰剂对活产的影响。泼尼松组活产率37.8%(135/357)与安慰剂组38.8%(139/358)无显著差异(绝对差-1.0%,95%CI -8.1%至6.1%;RR 0.97,95%CI 0.81至1.17;P=0.78)。作者结论认为泼尼松未改善活产率,数据提示可能增加早产和生化妊娠丢失风险。
要点
- 反复种植失败患者中,泼尼松组活产率37.8%与安慰剂组38.8%无显著差异(RR 0.97,95%CI 0.81至1.17;P=0.78)。
- 泼尼松组生化妊娠丢失率17.3% vs 安慰剂组9.9%(RR 1.75,95%CI 1.03至2.99;P=0.04)。
- 泼尼松组早产率11.8% vs 安慰剂组5.5%(RR 2.14,95%CI 1.00至4.58;P=0.04)。
核心结论
- 在反复种植失败患者中,与安慰剂相比,泼尼松治疗未改善活产率。
- 数据提示泼尼松使用可能增加早产和生化妊娠丢失的风险。
- 作者认为该结果挑战了泼尼松在临床实践中用于治疗反复种植失败的价值。
研究设计与样本
- 双盲、安慰剂对照、随机临床试验,在中国8家生殖中心开展。
- 纳入2018年11月至2020年8月期间入组、最终随访至2021年8月的妇女,纳入条件为有2次及以上胚胎移植失败史、取卵时年龄小于38岁、计划行冻融胚胎移植且有好质量胚胎可用。
- 共随机化715例妇女(平均年龄32岁),按1:1随机分配至口服10 mg泼尼松组(n=357)或匹配安慰剂组(n=358),每日一次,从开始子宫内膜准备当日用至早期妊娠。
- 714例(99.9%)有活产结局数据并纳入主要分析。
- 主要结局为活产,定义为妊娠28周及以上娩出任何数量有生命体征的新生儿。
主要发现
- 泼尼松组活产率37.8%(135/357)vs 安慰剂组38.8%(139/358),绝对差-1.0%(95%CI -8.1%至6.1%),RR 0.97(95%CI 0.81至1.17),P=0.78。
- 泼尼松组生化妊娠丢失率17.3% vs 安慰剂组9.9%,绝对差7.5%(95%CI 0.6%至14.3%),RR 1.75(95%CI 1.03至2.99),P=0.04。
- 泼尼松组早产率11.8% vs 安慰剂组5.5%,绝对差6.3%(95%CI 0.2%至12.4%),RR 2.14(95%CI 1.00至4.58),P=0.04。
- 两组在生化妊娠率、临床妊娠率、种植率、新生儿并发症、先天畸形、其他不良事件及平均出生体重方面均无统计学显著差异。
临床怎么用
- 作者结论认为,在反复种植失败患者中,泼尼松治疗未改善活产率,该结果挑战了泼尼松在此类患者临床实践中的使用价值。
- 作者指出数据提示泼尼松使用可能增加早产和生化妊娠丢失的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Implantation failure remains a critical barrier to in vitro fertilization. Prednisone, as an immune-regulatory agent, is widely used to improve the probability of implantation and pregnancy, although the evidence for efficacy is inadequate. OBJECTIVE: To determine the efficacy of 10 mg of prednisone compared with placebo on live birth among women with recurrent implantation failure. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, placebo-controlled, randomized clinical trial conducted at 8 fertility centers in China. Eligible women who had a history of 2 or more unsuccessful embryo transfer cycles, were younger than 38 years when oocytes were retrieved, and were planning to undergo frozen-thawed embryo transfer with the availability of good-quality embryos were enrolled from November 2018 to August 2020 (final follow-up August 2021). INTERVENTIONS: Participants were randomized (1:1) to receive oral pills containing either 10 mg of prednisone (n = 357) or matching placebo (n = 358) once daily, from the day at which they started endometrial preparation for frozen-thawed embryo transfer through early pregnancy. MAIN OUTCOMES AND MEASURES: The primary outcome was live birth, defined as the delivery of any number of neonates born at 28 or more weeks' gestation with signs of life. RESULTS: Among 715 women randomized (mean age, 32 years), 714 (99.9%) had data available on live birth outcomes and were included in the primary analysis. Live birth occurred among 37.8% of women (135 of 357) in the prednisone group vs 38.8% of women (139 of 358) in the placebo group (absolute difference, -1.0% [95% CI, -8.1% to 6.1%]; relative ratio [RR], 0.97 [95% CI, 0.81 to 1.17]; P = .78). The rates of biochemical pregnancy loss were 17.3% in the prednisone group and 9.9% in the placebo group (absolute difference, 7.5% [95% CI, 0.6% to 14.3%]; RR, 1.75 [95% CI, 1.03 to 2.99]; P = .04). Of those in the prednisone group, preterm delivery occurred among 11.8% and of those in the placebo group, 5.5% of pregnancies (absolute difference, 6.3% [95% CI, 0.2% to 12.4%]; RR, 2.14 [95% CI, 1.00 to 4.58]; P = .04). There were no statistically significant between-group differences in the rates of biochemical pregnancy, clinical pregnancy, implantation, neonatal complications, congenital anomalies, other adverse events, or mean birthweights. CONCLUSIONS AND RELEVANCE: Among patients with recurrent implantation failure, treatment with prednisone did not improve live birth rate compared with placebo. Data suggested that the use of prednisone may increase the risk of preterm delivery and biochemical pregnancy loss. Our results challenge the value of prednisone use in clinical practice for the treatment of recurrent implantation failure. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR1800018783.
引用
- Sun Y, Cui L, Lu Y, et al. Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization: A Randomized Clinical Trial. JAMA. 2023. PMID: 37129654. doi:10.1001/jama.2023.5302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。